The main systemic therapy for RCC in VHL syndrome targets HIF-2α and MTOR-P13K-HIF-α pathways, and our meta-analysis showed that molecules targeting these pathways are viable non-invasive interventions with a variable response rate and toxicity. Here, EPAS1 is linked to renal cell carcinoma.